drugset / Trial / NCT04390334

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

NCT04390334

Phase 1 Completed 24 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

A study in healthy male subjects to investigate the effect of famotidine and efavirenz on the way the body takes up, distributes, and gets rid of daridorexant.

Timeline

Start
2020-05-13
Primary completion
2020-06-26
Completion
2020-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral
Subject Efavirenz Other / unclassified 600 mg Oral
Subject Famotidine Other / unclassified 40 mg Oral

Indications

No indication recorded.